| Schedule of revenues disaggregated by category |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
2023 |
|
2022 |
|
2021 |
Product sales: |
|
|
|
|
|
|
|
|
|
Gross product sales |
|
$ |
147,058 |
|
$ |
108,523 |
|
$ |
81,186 |
Discounts and allowances |
|
|
(42,764) |
|
|
(31,805) |
|
|
(18,176) |
Total product sales, net |
|
|
104,294 |
|
|
76,718 |
|
|
63,010 |
Revenues from collaborations: |
|
|
|
|
|
|
|
|
|
License revenues |
|
|
— |
|
|
7,932 |
|
|
70,553 |
Milestone revenue |
|
|
75 |
|
|
25,000 |
|
|
1,875 |
Delivery of drug supplies, royalty and others |
|
|
11,413 |
|
|
6,092 |
|
|
3,298 |
Total revenues from collaborations |
|
|
11,488 |
|
|
39,024 |
|
|
75,726 |
Government contracts |
|
|
1,100 |
|
|
4,500 |
|
|
10,500 |
Total revenues |
|
$ |
116,882 |
|
$ |
120,242 |
|
$ |
149,236 |
|
| Schedule of product revenue allowance and reserve categories |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2023 |
|
$ |
6,213 |
|
$ |
2,636 |
|
$ |
3,296 |
|
$ |
12,145 |
Provision related to current period sales |
|
|
32,330 |
|
|
8,299 |
|
|
869 |
|
|
41,498 |
Credit or payments made during the period |
|
|
(30,307) |
|
|
(7,418) |
|
|
(234) |
|
|
(37,959) |
Balance as of December 31, 2023 |
|
$ |
8,236 |
|
$ |
3,517 |
|
$ |
3,931 |
|
$ |
15,684 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2022 |
|
$ |
3,404 |
|
$ |
2,494 |
|
$ |
2,017 |
|
$ |
7,915 |
Provision related to current period sales |
|
|
23,488 |
|
|
5,901 |
|
|
1,514 |
|
|
30,903 |
Credit or payments made during the period |
|
|
(20,679) |
|
|
(5,759) |
|
|
(235) |
|
|
(26,673) |
Balance as of December 31, 2022 |
|
$ |
6,213 |
|
$ |
2,636 |
|
$ |
3,296 |
|
$ |
12,145 |
|